81 results about "Safety profile" patented technology

Pharmaceutical compositions comprising modafinil in the form of particles of defined size. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.

The instant invention provides a method for establishing safety profiles for chemical compounds, as well as pharmacological profiling said method comprising (A) testing the effects of said chemical compounds on the amount and / or post-translational modifications of two or more macromolecules in intact cells; (B) constructing a pharmacological profile based on the results of said tests; and (C) comparing said profile to the profile(s) of drugs with established safety characteristics. Additionally, the invention is also directed to a composition comprising an assay panel, said panel comprising at least one high-content assay for the amount and / or post-translational modification of a protein and at least one high-content assay for the amount and / or subcellular location of a protein-protein interaction.

Compounds that inhibit protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved safety profile due to low CYP3A4 inhibition, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

Inhalant anesthetics are developed with a number of properties including rapid onset and recovery, controllability, and, ideally, a broad safety profile. The efficacy of these agents is measured by their ability to create anesthesia within the framework of the other desirable properties. The instant invention focuses on the dosage level where analgesia occurs but amnesia or lack of consciousness does not. In addition to identifying the dosage level where pain is sharply reduced or eliminated but awareness remains, a delivery system for safe and effective delivery of the agent is described.

A fastener driving apparatus includes a vacuum piston and a drive piston, which vacuum piston, when moved (by way of a motor and linear motion converter), draws a vacuum against the drive piston, which drive piston may be held in place by retention means. An anvil is coupled to the drive piston. The retention means is released electrically or mechanically at or near the point of maximum vacuum volume. This drive piston and anvil assembly is then driven by atmospheric pressure and may strike as fastener to drive it into a substrate. At least one position sensor may be used. Once the fastener is driven, the apparatus may reset to an initial position. At least one valve may be included to dump the energy stored in the vacuum in the case of a jam condition, thus providing good safety profile.

The invention discloses a method and a system for detecting train positioning on the basis of dynamic adjustment. The technical scheme includes that the method comprises initially positioning trains from non-positioning phases to positioning phases; computing the dynamic distance measurement accuracy whenever the trains are completely initially positioned and then run through every two continuous transponders and effective messages of the transponders are received; computing uncertain values of the locations of the trains on the basis of dynamic distance measurement accuracy computation results and determining safety profiles of the locations of the trains according to the uncertain values of the locations of the trains. The method and the system have the advantages that the train positioning accuracy can be improved to the greatest extent, the arrangement quantity of the trackside transponders can be reduced, and accordingly the engineering cost can be lowered.

The present invention provides methods of treating IgE-associated disorders and products for use therein. The methods comprise administering to a subject an amount of a first composition comprising an immunogenie antigen and an amount of a second composition that inhibits the activity of IgE. The methods are particularly useful in treatment of allergies such as allergic rhinitis. These combination methods offer significant advantages, such as improving the efficacy of therapy while showing a good safety profile.

The present invention generally relates to a method for an improved treatment for Alzheimer's disease (AD) using immunotherapy, e.g., immunotherapy targeting β amyloid (Aβ), e.g., immunotherapy based on AN1792. In one embodiment, the method allows for predicting an adverse clinical response, and therefore allows for an improved safety profile of AN1792. In another embodiment, the method allows for predicting a favorable clinical response, and therefore allows for an improved efficacy profile of AN1792. The methods of the present invention may be combined to predict a favorable clinical response and the lack of an adverse clinical response.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

This invention relates to novel compositions of botulinum toxin that can be applied topically for various therapeutic, aesthetic and / or cosmetic purposes. The compositions may include botulinum toxin complexes, wherein the amounts of hemagglutinin, non-toxin non-hemagglutinin and / or exogenous albumin are selectively and independently reduced compared to conventional commercially available botulinum toxin. The compositions may further contain molecules that are not native to botulinum toxin and that bind non-covalently to the botulinum toxin complexes, thereby acting as skin-tropic “adhesion molecules” to improve the ability of the toxin complexes to adhere to and to penetrate the skin epithelium. The compositions have an improved safety profile compared to existing botulinum-containing compositions that are injected subcutaneously. Methods for the use of such compositions are also contemplated by this invention.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

A fluticasone lotion having improved vasoconstrictor and anti-inflammatory activity and higher than expected potency. The fluticasone lotion contains 0.05 weight percent fluticasone propionate and an oil-in-water vehicle that includes excipients. The fluticasone lotion is unexpectedly efficacious while exhibiting an improved safety profile.

A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit / risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ≦12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg / day of Campath-1H for a period of 1-5 consecutive days.

A saline-filled breast prosthesis has enhanced performance by virtue of having tactile characteristics approximating those of gel-filled implants. The invention retains all the benefits of the recognized safety profile, straight-forward construction, and broad clinical indications for saline implants. An enhanced implantable mammary prosthesis comprises a shell, a slurry filler compartment interior to the shell containing slurry filler, a fluid compartment, the fluid compartment being deformable from a neutral profile under pressure from the slurry filler and which recoils to the neutral profile when not under pressure, a reservoir, the reservoir being disposed external to the shell, the reservoir and fluid compartment being fluidically coupled by a port, and a limiting membrane region disposed between the fluid compartment and the reservoir.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital / perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital / perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital / perianal warts are also disclosed and described.

A saline-filled breast prosthesis has enhanced performance by virtue of having tactile characteristics approximating those of gel-filled implants. The invention retains all the benefits of the recognized safety profile, straight-forward construction, and broad clinical indications for saline implants. An enhanced implantable mammary prosthesis comprises a shell, a slurry filler compartment interior to the shell containing slurry filler, a fluid compartment, the fluid compartment being deformable from a neutral profile under pressure from the slurry filler and which recoils to the neutral profile when not under pressure, a reservoir, the reservoir being disposed external to the shell, the reservoir and fluid compartment being fluidically coupled by a port, and a limiting membrane region disposed between the fluid compartment and the reservoir.

The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

Disclosed herein are topical compositions of 5-α reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-α reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects.

The present invention relates to a more efficient chafing dish basin or Bain Marie for the hotel / catering and hospitality industry, that has a first exterior basin with a heating element, a second basin comprising an insulating base, one or more heat conductive layers and a third food basin. The first exterior basin has a heating element that extends through the insulation base, and heat conductive layer(s) to contact the bottom of the food basin. The heating element can be heated by naked flames or electrically. Sufficient heat is transferred to the food basin to obviate the need for water or allows for significantly less water to be used, increasing the safety profile of these chafing dishes.

A rear impact system for an electric vehicle includes a left crash beam coupled with a rear portion of a rear wheel arch of the electric vehicle and extending to a rear bumper of the electric vehicle and a right crash beam coupled with the rear portion of the rear wheel arch and extending to the rear bumper. Each of the left crash beam and the right crash beam defines a generally octagonal shape. Each of the left crash beam and the right crash beam defines an interior comprising a plurality of ribs extending in a longitudinal direction.

HA-based functional probes and a multiplexed targeting strategy for detection and isolation of invasive subpopulations in breast cancer cell lines. Methods for using HA metabolism for profiling and sorting breast cancer heterogeneity. As such, HA-based functional probes have appropriate targeting capacity and safety profiles for development as imaging and therapeutic agents for following repair and neoplastic disease processes such as breast cancer.

Pharmaceutical compositions comprising modafinil in the form of particles of defined size and methods for preparing same. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.

It is an object of the invention to provide a composition with an excellent action of inhibiting vascularization, as prepared by a simple method suitable for actual production from an inexpensive, relatively readily available material without any problematic safety profile at an industrial scale without any complicated purification step. The composition is a composition for inhibiting vascularization, which contains a barley-derived ingredient selected from the group consisting of an unpolished barley ethyl alcohol extract fraction, an unpolished barley alkali extract fraction and fermented barley (preferably, a residual solution from the distillation of barley distilled spirits) as the active component with an action of inhibiting vascularization. The composition for inhibiting vascularization is a composition for therapeutically treating or preventing diseases which vascularization should be inhibited, specifically diseases with an etiology of abnormal vascularization in tumor or cancer, chronic inflammation or retinopathy. The composition is in a form selected from the group consisting of food additives, food materials, foods and drinks, pharmaceutical products under regulations by the Ministry of Health and Labor in Japan and quasi-pharmaceutical products under regulations by the Ministry of Health and Labor in Japan, and feeds.

Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.